Childhood vaccination schedule: Difference between revisions
Line 455: | Line 455: | ||
|- | |- | ||
| rowspan="2" align="left" style="background:#DCDCDC;"|Rotavirus<sup>2</sup> | | rowspan="2" align="left" style="background:#DCDCDC;"|Rotavirus<sup>2</sup> | ||
| rowspan="2" | | | rowspan="2" style="background:#F8F8FF; | | ||
|align="center" style="background: #FF7F50; padding: 5px text-align:center" | | |align="center" style="background: #FF7F50; padding: 5px text-align:center" | | ||
| colspan="2" rowspan="2" align="center" style="background: #FF7F50; padding: 5px text-align:center" | | | colspan="2" rowspan="2" align="center" style="background: #FF7F50; padding: 5px text-align:center" | | ||
Line 463: | Line 463: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Diphtheria, tetanus, & acellular pertussis<sup>3</sup> (DTaP) | |align="left" style="background:#DCDCDC;"|Diphtheria, tetanus, & acellular pertussis<sup>3</sup> (DTaP) | ||
| | |style="background:#F8F8FF; | | ||
| colspan="9" style="background: #F0E68C; padding: 5px text-align:center" | | | colspan="9" style="background: #F0E68C; padding: 5px text-align:center" | | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Haemophilus influenzae type b<sup>4</sup> | |align="left" style="background:#DCDCDC;"|Haemophilus influenzae type b<sup>4</sup> | ||
| | |style="background:#F8F8FF; | | ||
| colspan="3" style="background: #DAA520; padding: 5px text-align:center" | | | colspan="3" style="background: #DAA520; padding: 5px text-align:center" | | ||
| colspan="3" style="background: #F0E68C; padding: 5px text-align:center" | | | colspan="3" style="background: #F0E68C; padding: 5px text-align:center" | | ||
Line 474: | Line 474: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Pneumococcal conjugate<sup>5</sup> | |align="left" style="background:#DCDCDC;"|Pneumococcal conjugate<sup>5</sup> | ||
| | |style="background:#F8F8FF; | | ||
| colspan="4" style="background: #DAA520; padding: 5px text-align:center" | | | colspan="4" style="background: #DAA520; padding: 5px text-align:center" | | ||
|style="background: #F0E68C; padding: 5px text-align:center" | | |style="background: #F0E68C; padding: 5px text-align:center" | | ||
Line 514: | Line 514: | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Human papillomavirus<sup>13</sup> | |align="left" style="background:#DCDCDC;"|Human papillomavirus<sup>13</sup> | ||
| | |style="background:#F8F8FF; | | ||
| colspan="3" style="background: #DAA520; padding: 5px text-align:center" | | | colspan="3" style="background: #DAA520; padding: 5px text-align:center" | | ||
| colspan="6" style="background: #F0E68C; padding: 5px text-align:center" | | | colspan="6" style="background: #F0E68C; padding: 5px text-align:center" | | ||
|- | |- | ||
|align="left" style="background:#DCDCDC;"|Meningococcal B<sup>11</sup> | |align="left" style="background:#DCDCDC;"|Meningococcal B<sup>11</sup> | ||
| | |style="background:#F8F8FF; | | ||
| colspan="6" style="background: #DA70D6; padding: 5px text-align:center" | | | colspan="6" style="background: #DA70D6; padding: 5px text-align:center" | | ||
|style="background: #DAA520; padding: 5px text-align:center" | | |style="background: #DAA520; padding: 5px text-align:center" | | ||
Line 527: | Line 527: | ||
|style="background: #DA70D6; padding: 5px text-align:center" | | |style="background: #DA70D6; padding: 5px text-align:center" | | ||
| colspan="9" style="background: #DAA520; padding: 5px text-align:center" | | | colspan="9" style="background: #DAA520; padding: 5px text-align:center" | | ||
|} | |||
{| class="wikitable" | |||
|style="background: #F0E68C; padding: 5px text-align:center" | | |||
|Vaccination according to the routine schedule recommended | |||
|- | |||
|style="background: #DA70D6; padding: 5px text-align:center" | | |||
|Recommended for persons with an additional risk factor for which the vaccine would be indicated | |||
|- | |||
|style="background: #DAA520; padding: 5px text-align:center" | | |||
|Vaccination is recommended, and additional doses may be necessary based on medical condition. See footnotes. | |||
|- | |||
|align="left" style="background:#DCDCDC;" | |||
|No recommendation | |||
|- | |||
|align="center" style="background: #A52A2A; padding: 5px text-align:center" | | |||
|Contraindicated | |||
|- | |||
|align="center" style="background: #FF7F50; padding: 5px text-align:center" | | |||
|Precaution for vaccination | |||
|} | |} | ||
Revision as of 19:26, 13 April 2017
Template:Vaccination schedule Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]
Overview
Childhood vaccination schedule
The following table summarizes the vaccination schedule for Adolescents Aged 18 Years or Younger based on CDC 2017 recommendation.
Vaccine | Birth | 1 mo | 2 mos | 4 mos | 6 mos | 9 mos | 12 mos | 15 mos | 18 mos | 19-23 mos | 2-3 yrs | 4-6 yrs | 7-10 yrs | 11-12 yrs | 13-15 yrs | 16 yrs | 17-18 yrs | ||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Hepatitis B1 (Hep B) | 1st dose | 2nd dose | 3rd dose | ||||||||||||||||
Rotavirus2 (RV) RV1 (2-dose series);
RV5 (3-dose series) |
1st dose | 2nd dose | See footnote 2 | ||||||||||||||||
Diphtheria, tetanus, & acellular pertussis3
(DTaP: <7 yrs) |
1st dose | 2nd dose | 3rd dose | 4th dose | 5th dose | ||||||||||||||
Haemophilus influenzae type b4 (Hib) | 1st dose | 2nd dose | See footnote 4 | 3rd or 4th dose,
See footnote 4 |
|||||||||||||||
Pneumococcal conjugate5 (PCV13) | 1st dose | 2nd dose | 3rd dose | 4th dose | |||||||||||||||
Inactivated poliovirus6 (IPV: <18 yrs) | 1st dose | 2nd dose | 3rd dose | 4th dose | |||||||||||||||
Influenza7 (IIV) | Annual vaccination (IIV) 1 or 2 doses | Annual vaccination (IIV) 1 dose only | |||||||||||||||||
Measles, mumps, rubella8 (MMR) | See footnote 8 | 1st dose | 2nd dose | ||||||||||||||||
Varicella9 (VAR) | 1st dose | 2nd dose | |||||||||||||||||
Hepatitis A10 (Hep A) | 2-dose series, See footnote 10 | ||||||||||||||||||
Meningococcal11 (Hib-MenCY >6 weeks;
MenACWY-D >9 mos; MenACWY-CRM ≥2 mos) |
See footnote 11 | 1st dose | 2nd dose | ||||||||||||||||
Tetanus, diphtheria, & acellular pertussis12 (Tdap: >7 yrs) | Tdap | ||||||||||||||||||
Human papillomavirus13 (HPV) | See footnote 13 | ||||||||||||||||||
Meningococcal B11 | See footnote 11 | ||||||||||||||||||
Pneumococcal polysaccharide5 (PPSV23) | See footnote 5 |
Range of recommended ages for all children | |
Range of recommended ages for catch-up immunization | |
No recommendation | |
Range of recommended ages for certain high-risk groups |
Catch-up immunization
Catch-up immunization schedule for persons aged 4 months through 18 years who start late or who are more than 1 month behind.
The table below provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use the section appropriate for the child’s age. Always use this table in conjunction with above table and the footnotes that follow.
Children age 4 months through 6 years | |||||
---|---|---|---|---|---|
Vaccine | Minimum Age for Dose 1 | Minimum Interval Between Doses | |||
Dose 1 to Dose 2 | Dose 2 to Dose 3 | Dose 3 to Dose 4 | Dose 4 to Dose 5 | ||
Hepatitis B1 | Birth | 4 weeks | 8 weeks
and at least 16 weeks after first dose. Minimum age for the final dose is 24 weeks. |
||
Rotavirus2 | 6 weeks | 4 weeks | 4 weeks2 | ||
Diphtheria, tetanus, and acellular pertussis3 | 6 weeks | 4 weeks | 4 weeks | 6 months | 6 months3 |
Haemophilus influenzae type b4 | 6 weeks |
|
If current age is younger than 12 months and first dose was administered at younger than age 7 months, and at least 1 previous dose was PRP-T (ActHib, Pentacel, Hiberix) or unknown.
and age 12 through 59 months (as final dose)4 If current age is younger than 12 months and first dose was administered at age 7 through 11 months; OR If current age is 12 through 59 months and first dose was administered before the 1st birthday, and second dose administered at younger than 15 months; OR If both doses were PRP-OMP (PedvaxHIB; Comvax) and were administered before the 1st birthday.
|
This dose only necessary for children age 12 through 59 months who received 3 doses before the 1st birthday. |
|
Pneumococcal5 | 6 weeks |
|
|
This dose only necessary for children aged 12 through 59 months who received 3 doses before age 12 months or for children at high risk who received 3 doses at any age. |
|
Inactivated poliovirus6 | 6 weeks | 4 weeks6 | 4 weeks6 | 6 months6 (minimum age 4 years for final dose). | |
Measles, mumps, rubella8 | 12 months | 4 weeks | |||
Varicella9 | 12 months | 3 months | |||
Hepatitis A10 | 12 months | 6 months | |||
Meningococcal11 (Hib-MenCY ≥6 weeks; MenACWY-D ≥9 mos; MenACWY-CRM ≥2 mos) | 6 weeks | 8 weeks11 | See footnote 11 | See footnote 11 |
Children and adolescents age 7 through 18 years | |||||
---|---|---|---|---|---|
Vaccine | Minimum Age for Dose 1 | Minimum Interval Between Doses | |||
Dose 1 to Dose 2 | Dose 2 to Dose 3 | Dose 3 to Dose 4 | Dose 4 to Dose 5 | ||
Meningococcal11
(MenACWY-D ≥9 mos; MenACWY-CRM ≥2 mos) |
Not Applicable (N/A) | 8 weeks11 | |||
Tetanus, diphtheria;
Tetanus, diphtheria, and acellular pertussis12 |
7 years12 | 4 weeks |
|
If first dose of DTaP/DT was administered before the 1st birthday. |
|
Human papillomavirus13 | 9 years | Routine dosing intervals are recommended.13 | |||
Hepatitis A10 | N/A | 6 months | |||
Hepatitis B1 | N/A | 4 weeks | 8 weeks and at least 16 weeks after first dose. | ||
Inactivated poliovirus6 | N/A | 4 weeks | 4 weeks6 | 6 months6 | |
Measles, mumps, rubella8 | N/A | 4 weeks | |||
Varicella9 | N/A |
|
Specific conditions
Vaccines that might be indicated for children and adolescents aged 18 years or younger based on medical indications.
VACCINE | Pregnancy | Immunocompromised status (excluding HIV infection) | HIV infection CD4+ count (cells/μL) | Kidney failure, endstage renal disease, on hemodialysis | Heart disease, chronic lung disease | CSF leaks/ cochlear implants | Asplenia and persistent complement component deficiencies | Chronic liver disease | Diabetes | |
---|---|---|---|---|---|---|---|---|---|---|
<15% of total CD4 cell count | ≥15% of total CD4 cell count | |||||||||
Hepatitis B1 | ||||||||||
Rotavirus2 | ||||||||||
SCID | ||||||||||
Diphtheria, tetanus, & acellular pertussis3 (DTaP) | ||||||||||
Haemophilus influenzae type b4 | ||||||||||
Pneumococcal conjugate5 | ||||||||||
Inactivated poliovirus6 | ||||||||||
Influenza7 | ||||||||||
Measles, mumps, rubella8 | ||||||||||
Varicella9 | ||||||||||
Hepatitis A10 | ||||||||||
Meningococcal ACWY11 | ||||||||||
Tetanus, diphtheria, & acellular pertussis12 (Tdap) | ||||||||||
Human papillomavirus13 | ||||||||||
Meningococcal B11 | ||||||||||
Pneumococcal polysaccharide5 |
Vaccination according to the routine schedule recommended | |
Recommended for persons with an additional risk factor for which the vaccine would be indicated | |
Vaccination is recommended, and additional doses may be necessary based on medical condition. See footnotes. | |
align="left" style="background:#DCDCDC;" | No recommendation |
Contraindicated | |
Precaution for vaccination |
See also
Sources and notes
External links
- National Center for Immunization and Respiratory Diseases. "CDC National Immunization Program". CDC. Retrieved 2006-09-18.
- "MMR vaccine and the autism epidemic: In a compulsory inoculation program, it is the responsibility of the developers, promoters and enforcers to prove safety and efficacy". MMR vaccine and the autism epidemic. InformedChoice.info. Retrieved 2006-09-18.
- National Health Service of UK. "UK Immunisation Schedule and Information". NHS. Retrieved 2006-11-03.
de:Impfkalender id:Jadwal imunisasi